STOCK TITAN

VBI Vaccines Inc. - VBIV STOCK NEWS

Welcome to our dedicated page for VBI Vaccines news (Ticker: VBIV), a resource for investors and traders seeking the latest updates and insights on VBI Vaccines stock.

VBI Vaccines Inc. (NASDAQ: VBIV) is a leading biopharmaceutical company focused on developing next-generation vaccines to meet unmet needs in infectious diseases and immuno-oncology. Headquartered in Cambridge, MA, with research facilities in Ottawa, Canada, VBI is at the forefront of vaccine innovation with two primary platforms.

The first platform, Enveloped Virus-Like Particle (eVLP), enables the design of vaccines that closely mimic the target virus, enhancing their effectiveness. The company's lead eVLP asset is a prophylactic cytomegalovirus (CMV) vaccine, currently advancing with GMP manufacturing for formal preclinical and Phase I trials.

The second platform is a thermostable technology allowing vaccines and biologics to withstand fluctuating temperatures during storage and transport. VBI has completed proof-of-concept thermostability studies on several vaccine and biologic targets, highlighting this platform's potential to improve global vaccine distribution.

VBI's commercial product, Sci-B-Vac, is a hepatitis B (HBV) vaccine approved for adults, children, and newborns. The company's innovations are designed to address significant gaps in the vaccine market, particularly in underserved areas.

Recent achievements include the initiation of GMP manufacturing for its CMV vaccine candidate and successful proof-of-concept studies for its thermostable technology. VBI continues to be a pivotal player in the biopharmaceutical field, dedicated to advancing public health through cutting-edge vaccine solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
clinical trial covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.42%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none

FAQ

What does VBI Vaccines Inc. focus on?

VBI Vaccines Inc. focuses on developing next-generation vaccines to address unmet needs in infectious diseases and immuno-oncology.

Where is VBI Vaccines Inc. headquartered?

VBI Vaccines Inc. is headquartered in Cambridge, MA, with research facilities in Ottawa, Canada.

What is the eVLP platform?

The eVLP platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus, enhancing their effectiveness.

What is VBI's lead eVLP asset?

VBI's lead eVLP asset is a prophylactic cytomegalovirus (CMV) vaccine currently advancing with GMP manufacturing for preclinical and Phase I trials.

What is the thermostable technology platform?

The thermostable technology platform enables the development of vaccines and biologics that can withstand fluctuating temperatures during storage and transport.

What is Sci-B-Vac?

Sci-B-Vac is a hepatitis B (HBV) vaccine developed by VBI Vaccines Inc. for adults, children, and newborns.

What are the recent achievements of VBI Vaccines Inc.?

Recent achievements include the initiation of GMP manufacturing for its CMV vaccine candidate and successful proof-of-concept studies for its thermostable technology.

What markets does VBI aim to serve?

VBI aims to serve large underserved markets, addressing significant gaps in the vaccine market, particularly in infectious diseases and immuno-oncology.

How does VBI's thermostable technology benefit global vaccine distribution?

VBI's thermostable technology benefits global vaccine distribution by enabling vaccines to withstand fluctuating temperatures during storage and transport, improving their accessibility in diverse regions.

What stage is VBI's CMV vaccine candidate currently in?

VBI's CMV vaccine candidate is currently in the GMP manufacturing stage, advancing towards formal preclinical and Phase I trials.

VBI Vaccines Inc.

Nasdaq:VBIV

VBIV Rankings

VBIV Stock Data

17.06M
28.68M
6.77%
13.03%
0.96%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE